

## Supplemental Online Content

Ferreira JP, Zannad F, Butler J, et al. Association of empagliflozin treatment with albuminuria levels in patients with heart failure: a secondary analysis of EMPEROR-Pooled. *JAMA Cardiol*. Published online September 21, 2022. doi:10.1001/jamacardio.2022.2924

**eTable 1.** Safety by baseline UACR

**eTable 2.** Effect of Empagliflozin on relative change in UACR at Week 52 by baseline UACR and diabetes status (adjusted\* gMean ratio 95% Confidence Interval)

This supplemental material has been provided by the authors to give readers additional information about their work.

eTable 1. Safety by baseline UACR

	Baseline UACR Category					
	Normal (<30 mg/dL)		Microalbuminuria (30 to ≤300 mg/dL)		Macroalbuminuria (>300 mg/dL)	
	Placebo	Empagliflozin	Placebo	Empagliflozin	Placebo	Empagliflozin
Number of patients	2783 (100.0)	2765 (100.0)	1548 (100.0)	1546 (100.0)	500 (100.0)	525 (100.0)
With any AE	2242 ( 80.6)	2221 ( 80.3)	1337 ( 86.4)	1292 ( 83.6)	453 ( 90.6)	469 ( 89.3)
With AE leading to treatment discontinuation	394 ( 14.2)	427 ( 15.4)	339 ( 21.9)	323 ( 20.9)	138 ( 27.6)	140 ( 26.7)
With serious AE	1240 ( 44.6)	1125 ( 40.7)	872 ( 56.3)	777 ( 50.3)	316 ( 63.2)	300 ( 57.1)
Acute renal failure <sup>a</sup>	270 ( 9.7)	233 ( 8.4)	203 ( 13.1)	205 ( 13.3)	99 ( 19.8)	100 ( 19.0)

<sup>a</sup> defined by MedDRA Query “Acute renal failure” (narrow scope)

AE: Adverse event; UACR, urinary albumin-to-creatinine ratio.

eTable 2. Effect of Empagliflozin on relative change in UACR at Week 52 by baseline UACR and diabetes status (adjusted\* gMean ratio 95% Confidence Interval)

	Placebo	Empagliflozin	p-value for interaction (trend)
Overall	(n=4740)	(n=4761)	
	0.975 (0.941, 1.011)	0.969 (0.935, 1.004)	
	0.994 (0.945, 1.045)		
Baseline UACR Category			0.0408
Normal (<30 mg/dL)	(n=2740)	(n=2730)	
	1.430 (1.365, 1.498)	1.481 (1.413, 1.551)	
	1.036 (0.970, 1.106)		
Microalbuminuria (30 to ≤300 mg/dL)	(n=1508)	(n=1512)	
	0.598 (0.561, 0.638)	0.571 (0.535, 0.608)	
	0.954 (0.872, 1.044)		
Macroalbuminuria (>300 mg/dL)	(n=492)	(n=519)	
	0.447 (0.399, 0.500)	0.393 (0.352, 0.438)	
	0.879 (0.751, 1.028)		
Baseline Diabetes Status			0.008
Diabetes	(n=2340)	(n=2337)	
	0.958 (0.910, 1.009)	0.872 (0.829, 0.918)	
	0.910 (0.847, 0.979)		
No Diabetes	(n=2400)	(n=2424)	
	0.956 (0.909, 1.005)	1.034 (0.984, 1.087)	
	1.082 (1.008, 1.161)		

Based on mixed model repeated measures (MMRM) analysis including age, baseline eGFR and baseline LVEF as linear covariates and study, region, baseline diabetes status, sex, log(baseline UACR) by visit, visit by treatment and week reachable as fixed effects (overall population). For the subgroup analysis visit by treatment by UACR subgroup was used.

eGFR, estimated glomerular filtration rate; UACR, urinary albumin-to-creatinine ratio.